Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Laxatives monograph clarification

This article was originally published in The Tan Sheet

Executive Summary

CHPA asks FDA to accept the statement of identity "fiber laxative" as well as "the indication 'Fiber therapy for relief of occasional constipation' [which may be followed by '(irregularity)']" in a Jan. 20 letter. The trade group also requests clarification on whether "'fiber laxative' may be used as an alternative to 'bulk-forming laxative.'" CHPA's request comes after the October 2003 reopening of the administrative record for OTC laxatives (1"The Tan Sheet" Oct. 27, 2003, In Brief)...

You may also be interested in...



Laxative record open

FDA is reopening the administrative record for OTC laxative products until Jan. 20, 2004, agency announces in Oct. 22 1Federal Register. Agency explains it "has received new data and information submitted to the rulemaking for OTC laxative drug products after the administrative record closed on the various dates" since the 1985 tentative final monograph. Separately, comments on the agency's proposal to reclassify granular psyllium as Category II (not generally recognized as safe and effective) from Category I (generally recognized as safe and effective) are due Nov. 3, FDA says (2"The Tan Sheet" Aug. 11, 2003, p. 10)...

Big Pharma BD Execs Tell Start-Ups: Don’t Be Afraid To Ask Us For Help

Business development leaders and venture capital investors spoke at Biocom’s annual partnering conference about what they are seeking in relationships with entrepreneurs and start-ups.

Transformation Into Viatris Not Seen As The Solution Mylan Needs

Mylan’s full year 2019 earnings report was its last as an independent company, so the focus was on the coming merger with Pfizer’s Upjohn and growth prospects for the new company, Viatris.

Topics

UsernamePublicRestriction

Register

PS096402

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel